NO20060706L - Inhibitorer av serinproteaser, spesielt HCV NS3-NS4A-protease - Google Patents

Inhibitorer av serinproteaser, spesielt HCV NS3-NS4A-protease

Info

Publication number
NO20060706L
NO20060706L NO20060706A NO20060706A NO20060706L NO 20060706 L NO20060706 L NO 20060706L NO 20060706 A NO20060706 A NO 20060706A NO 20060706 A NO20060706 A NO 20060706A NO 20060706 L NO20060706 L NO 20060706L
Authority
NO
Norway
Prior art keywords
compounds
disclosed
inhibitors
serine proteases
ns4a protease
Prior art date
Application number
NO20060706A
Other languages
English (en)
Norwegian (no)
Inventor
Janos Pitlik
Robert Perni
Shawn D Britt
Kevin M Cottrell
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34079432&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20060706(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of NO20060706L publication Critical patent/NO20060706L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Apparatus For Disinfection Or Sterilisation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
NO20060706A 2003-07-18 2006-02-14 Inhibitorer av serinproteaser, spesielt HCV NS3-NS4A-protease NO20060706L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48853503P 2003-07-18 2003-07-18
PCT/US2004/023054 WO2005007681A2 (en) 2003-07-18 2004-07-16 Inhibitors of serine proteases, particularly hcv ns3-ns4a protease

Publications (1)

Publication Number Publication Date
NO20060706L true NO20060706L (no) 2006-02-14

Family

ID=34079432

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20060706A NO20060706L (no) 2003-07-18 2006-02-14 Inhibitorer av serinproteaser, spesielt HCV NS3-NS4A-protease

Country Status (18)

Country Link
US (2) US7109172B2 (pt)
EP (3) EP1646642A2 (pt)
JP (2) JP4745230B2 (pt)
KR (2) KR20120013450A (pt)
CN (3) CN1852920B (pt)
AR (1) AR045916A1 (pt)
AU (2) AU2004257288A1 (pt)
BR (1) BRPI0412761A (pt)
CA (1) CA2532664A1 (pt)
IL (2) IL173180A0 (pt)
NO (1) NO20060706L (pt)
NZ (1) NZ544789A (pt)
PE (1) PE20050251A1 (pt)
RU (1) RU2412198C2 (pt)
TW (1) TW200523270A (pt)
UY (1) UY28423A1 (pt)
WO (1) WO2005007681A2 (pt)
ZA (1) ZA200601420B (pt)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ298749B6 (cs) * 1996-10-18 2008-01-16 Vertex Pharmaceuticals Incorporated Inhibitory serinových proteáz a farmaceutické prostředky s jejich obsahem
JP4806154B2 (ja) * 2000-04-03 2011-11-02 バーテックス ファーマシューティカルズ インコーポレイテッド セリンプロテアーゼ、特にｃ型肝炎ウイルスｎｓ３プロテアーゼのインヒビター
SV2003000617A (es) * 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
JP2005535574A (ja) * 2002-04-11 2005-11-24 バーテックス　ファーマシューティカルズ　インコーポレイテッド セリンプロテアーゼ、特にｈｃｖｎｓ３−ｎｓ４ａプロテアーゼのインヒビター
TW200510391A (en) * 2003-04-11 2005-03-16 Vertex Pharma Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
BRPI0412761A (pt) * 2003-07-18 2006-09-26 Vertex Pharma inibidores de serino proteases, particularmente a protease ns3-ns4a do vhc
PE20050374A1 (es) * 2003-09-05 2005-05-30 Vertex Pharma Inhibidores de proteasas de serina, en particular proteasa ns3-ns4a del vhc
CA2538791A1 (en) 2003-09-18 2005-03-31 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
CA2541634A1 (en) * 2003-10-10 2005-04-28 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
EP1677827B1 (en) * 2003-10-27 2008-12-10 Vertex Pharmaceuticals Incorporated Combinations for hcv treatment
EP2311851A3 (en) * 2004-02-04 2011-05-25 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
CN101218224B (zh) 2005-05-13 2013-05-08 Viro化学制药公司 治疗或预防黄病毒感染的组合物和方法
CN101212970B (zh) 2005-06-02 2010-07-21 先灵公司 Hcv蛋白酶抑制剂与表面活性剂的组合物
WO2006130686A2 (en) 2005-06-02 2006-12-07 Schering Corporation Hcv protease inhibitors in combination with food
CA2617679A1 (en) * 2005-08-02 2007-02-08 Steve Lyons Inhibitors of serine proteases
US8399615B2 (en) 2005-08-19 2013-03-19 Vertex Pharmaceuticals Incorporated Processes and intermediates
AR055395A1 (es) * 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
US7964624B1 (en) 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
US7705138B2 (en) 2005-11-11 2010-04-27 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants
AU2006315438A1 (en) 2005-11-11 2007-05-24 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants
CA2643688A1 (en) * 2006-02-27 2007-08-30 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical compositions comprising the same
WO2007109080A2 (en) 2006-03-16 2007-09-27 Vertex Pharmaceuticals Incorporated Deuterated hepatitis c protease inhibitors
CA2643680A1 (en) * 2006-04-11 2007-11-22 Novartis Ag Hcv/hiv inhibitors and their uses
CA2657618C (en) 2006-07-13 2016-10-11 Achillion Pharmaceuticals, Inc. 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
US20090035267A1 (en) * 2007-07-31 2009-02-05 Moore Joel D Acyclic, pyridazinone-derived hepatitis c serine protease inhibitors
EP1886685A1 (en) 2006-08-11 2008-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition
US20080108632A1 (en) * 2006-11-02 2008-05-08 Taigen Biotechnology Co., Ltd. Hcv protease inhibitors
PT2104674E (pt) 2006-11-15 2013-07-26 Virochem Pharma Inc Análogos de tiofeno para o tratamento ou prevenção de infeções por flavivírus
US20080161254A1 (en) * 2007-01-03 2008-07-03 Virobay, Inc. Hcv inhibitors
WO2008106058A2 (en) * 2007-02-27 2008-09-04 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
GEP20125645B (en) 2007-02-27 2012-09-25 Vertex Pharma Co-crystals and pharmaceutical compositions comprising the same
WO2008106167A1 (en) * 2007-02-28 2008-09-04 Conatus Pharmaceuticals, Inc. Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases
BRPI0808089A2 (pt) * 2007-02-28 2014-07-15 Conatus Pharmaceuticals Inc Método para tratar uma doença do fígado, para diminuir um nível elevado de uma enzima do fígado, para inibir uma cascata de sinalização de tnf-alfa e uma cascata de sinalização de alfa-faz, para reduzir um dano ao fígado, para suprimir a apoptose excessiva em uma célula de fígado, e para inibir a replicação do vírus da hepatite c.
US20090005387A1 (en) * 2007-06-26 2009-01-01 Deqiang Niu Quinoxalinyl macrocyclic hepatitis c virus serine protease inhibitors
WO2009032198A1 (en) 2007-08-30 2009-03-12 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical compositions comprising the same
ES2527166T3 (es) 2008-12-10 2015-01-21 Achillion Pharmaceuticals, Inc. Nuevos péptidos de 4-amino-4-oxobutanoílo como inhibidores de la replicación viral
US8512690B2 (en) * 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
US20110182850A1 (en) * 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
EP2477980B1 (en) 2009-09-15 2016-06-08 Taigen Biotechnology Co., Ltd. Hcv protease inhibitors
JP2013512247A (ja) 2009-11-25 2013-04-11 バーテックス ファーマシューティカルズ インコーポレイテッド フラビウイルス感染症の治療または予防のための５−アルキニル−チオフェン−２−カルボン酸誘導体およびそれらの使用
US20130072523A1 (en) 2009-12-24 2013-03-21 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
TW201141857A (en) 2010-03-24 2011-12-01 Vertex Pharma Analogues for the treatment or prevention of flavivirus infections
MX2012010918A (es) 2010-03-24 2013-01-18 Vertex Pharma Analogos para el tratamiento o prevencion de infecciones por flavivirus.
WO2011119870A1 (en) 2010-03-24 2011-09-29 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
TW201139438A (en) 2010-03-24 2011-11-16 Vertex Pharma Analogues for the treatment or prevention of flavivirus infections
WO2011156545A1 (en) 2010-06-09 2011-12-15 Vertex Pharmaceuticals Incorporated Viral dynamic model for hcv combination therapy
WO2011159826A2 (en) 2010-06-15 2011-12-22 Vertex Pharmaceuticals Incorporated Hcv ns5b protease mutants
JP2013531011A (ja) 2010-06-28 2013-08-01 バーテックス ファーマシューティカルズ インコーポレイテッド フラビウイルス感染の処置または予防のための化合物および方法
WO2012006070A1 (en) 2010-06-28 2012-01-12 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flavivirus infections
EP2585447A2 (en) 2010-06-28 2013-05-01 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flavivirus infections
MX2013001869A (es) 2010-08-17 2013-06-28 Vertex Pharma Compuestos y metodos para el tratamiento o prevencion de infecciones virales por flaviviridae.
WO2012107589A1 (en) 2011-02-11 2012-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment and prevention of hcv infections
WO2013016499A1 (en) 2011-07-26 2013-01-31 Vertex Pharmaceuticals Incorporated Methods for preparation of thiophene compounds
AU2012286853A1 (en) 2011-07-26 2013-05-02 Vertex Pharmaceuticals Incorporated Thiophene compounds
US20130123276A1 (en) 2011-11-14 2013-05-16 Sven Ruf Use of telaprevir and related compounds in atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases
EP2827876A4 (en) 2012-03-22 2015-10-28 Alios Biopharma Inc PHARMACEUTICAL COMBINATIONS WITH A THIONUCLEOTIDE ANALOG
WO2014053533A1 (en) 2012-10-05 2014-04-10 Sanofi Use of substituted 3-heteroaroylamino-propionic acid derivatives as pharmaceuticals for prevention/treatment of atrial fibrillation
TW201526899A (zh) 2013-02-28 2015-07-16 Alios Biopharma Inc 醫藥組成物
US9115175B2 (en) 2013-03-14 2015-08-25 Achillion Pharmaceuticals, Inc. Processes for Producing sovaprevir
JP2016513732A (ja) 2013-03-15 2016-05-16 アキリオン ファーマシューティカルズ，インコーポレーテッド ソバプレビル多形体およびその製造方法
WO2014145600A1 (en) 2013-03-15 2014-09-18 Achillion Pharmaceuticals, Inc. Ach-0142684 sodium salt polymorphs, composition including the same, and method of manufacture thereof
US9006423B2 (en) 2013-03-15 2015-04-14 Achillion Pharmaceuticals Inc. Process for making a 4-amino-4-oxobutanoyl peptide cyclic analogue, an inhibitor of viral replication, and intermediates thereof
WO2016069574A1 (en) * 2014-10-27 2016-05-06 Inhibrx Lp Serpin fusion polypeptides and methods of use thereof
WO2017222914A1 (en) 2016-06-21 2017-12-28 Inception 4, Inc. Carbocyclic prolinamide derivatives
EP4257191A3 (en) 2016-06-21 2023-11-22 Orion Ophthalmology LLC Heterocyclic prolinamide derivatives
US20220099637A1 (en) 2018-12-04 2022-03-31 Bristol-Myers Squibb Company Methods of analysis using in-sample calibration curve by multiple isotopologue reaction monitoring

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6387365B1 (en) 1995-05-19 2002-05-14 Schering Corporation Combination therapy for chronic hepatitis C infection
US6054472A (en) 1996-04-23 2000-04-25 Vertex Pharmaceuticals, Incorporated Inhibitors of IMPDH enzyme
US5807876A (en) 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
CZ298749B6 (cs) * 1996-10-18 2008-01-16 Vertex Pharmaceuticals Incorporated Inhibitory serinových proteáz a farmaceutické prostředky s jejich obsahem
AU6701598A (en) 1997-03-14 1998-09-29 Vertex Pharmaceuticals Incorporated Inhibitors of impdh enzyme
US6472373B1 (en) 1997-09-21 2002-10-29 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection
US6172046B1 (en) 1997-09-21 2001-01-09 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
DK1066247T3 (da) 1998-03-31 2007-04-02 Vertex Pharma Inhibitorer af serinproteaser, især hepatitis C virus NS3 protease
SK13332001A3 (sk) 1999-03-19 2002-02-05 Vertex Pharmaceuticals Incorporated Inhibítory IMPDH enzýmu a ich použitie
JP4806154B2 (ja) * 2000-04-03 2011-11-02 バーテックス ファーマシューティカルズ インコーポレイテッド セリンプロテアーゼ、特にｃ型肝炎ウイルスｎｓ３プロテアーゼのインヒビター
MXPA03000627A (es) * 2000-07-21 2004-07-30 Schering Corp Nuevos peptidos como inhibidores de proteasa serina-ns3 del virus de la hepatitis c.
AR029851A1 (es) * 2000-07-21 2003-07-16 Dendreon Corp Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
SV2003000617A (es) * 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
CA2449504A1 (en) * 2001-07-11 2003-01-23 Vertex Pharmaceuticals Incorporated Bridged bicyclic serine protease inhibitors
NZ531681A (en) * 2001-10-24 2007-05-31 Vertex Pharma Inhibitors of serine protease, particularly hepatitis C virus NS3-NS4A protease, incorporating a fused ring system
JP2005535574A (ja) * 2002-04-11 2005-11-24 バーテックス　ファーマシューティカルズ　インコーポレイテッド セリンプロテアーゼ、特にｈｃｖｎｓ３−ｎｓ４ａプロテアーゼのインヒビター
JP2005537861A (ja) 2002-09-04 2005-12-15 クオンタム ディヴァイスィズ，インコーポレイテッド 筋肉又は関節の痛みの処置のための電気光学装置及び方法
ATE547412T1 (de) * 2003-04-11 2012-03-15 Vertex Pharma Inhibitoren von serinproteasen, insbesondere hcv- ns3-ns4a-protease
TW200510391A (en) * 2003-04-11 2005-03-16 Vertex Pharma Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
BRPI0412761A (pt) * 2003-07-18 2006-09-26 Vertex Pharma inibidores de serino proteases, particularmente a protease ns3-ns4a do vhc
PE20050374A1 (es) * 2003-09-05 2005-05-30 Vertex Pharma Inhibidores de proteasas de serina, en particular proteasa ns3-ns4a del vhc
CA2538791A1 (en) 2003-09-18 2005-03-31 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
CA2541634A1 (en) 2003-10-10 2005-04-28 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
EP2311851A3 (en) 2004-02-04 2011-05-25 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
AR055395A1 (es) * 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
WO2008106058A2 (en) 2007-02-27 2008-09-04 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases

Also Published As

Publication number Publication date
AU2010257200B2 (en) 2011-10-20
US8691758B2 (en) 2014-04-08
NZ544789A (en) 2010-01-29
PE20050251A1 (es) 2005-04-13
RU2412198C2 (ru) 2011-02-20
JP2008500265A (ja) 2008-01-10
TW200523270A (en) 2005-07-16
US20050107304A1 (en) 2005-05-19
KR20060052836A (ko) 2006-05-19
CN102020700A (zh) 2011-04-20
EP2368900A3 (en) 2012-07-04
AU2004257288A2 (en) 2008-06-26
US7109172B2 (en) 2006-09-19
JP2011116784A (ja) 2011-06-16
AU2004257288A1 (en) 2005-01-27
EP1646642A2 (en) 2006-04-19
UY28423A1 (es) 2005-02-28
CN101724022A (zh) 2010-06-09
AR045916A1 (es) 2005-11-16
CN1852920A (zh) 2006-10-25
EP2341065A2 (en) 2011-07-06
CA2532664A1 (en) 2005-01-27
AU2010257200A1 (en) 2011-01-13
IL173180A0 (en) 2006-06-11
ZA200601420B (en) 2007-06-27
KR20120013450A (ko) 2012-02-14
CN1852920B (zh) 2010-12-15
EP2341065A3 (en) 2012-06-20
WO2005007681A3 (en) 2005-06-02
EP2368900A2 (en) 2011-09-28
IL218698A0 (en) 2012-05-31
HK1098164A1 (en) 2007-07-13
WO2005007681A2 (en) 2005-01-27
JP4745230B2 (ja) 2011-08-10
RU2006105002A (ru) 2006-08-27
BRPI0412761A (pt) 2006-09-26
US20060211629A1 (en) 2006-09-21

Similar Documents

Publication Publication Date Title
WO2005007681A3 (en) Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
NO20062101L (no) Serinproteaseinhibitorer, spesielt hcv ns3-ns4a-protease
TW200510391A (en) Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
WO2005077969A3 (en) Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
WO2004093798A3 (en) Quinoxalinyl macrocyclic hepatitis c serine protease inhibitors
WO2005035525A3 (en) 2-amido-4-aryloxy-1-carbonylpyrrolidine derivatives as inhibitors of serine proteases, particularly hcv ns3-ns4a protease
ATE349463T1 (de) Verbrückte bizyklische serinproteaseinhibitoren
WO2004113365A3 (en) Hepatitis c serine protease tri-peptide inhibitors
EP1441720B8 (en) Inhibitors of serine protease, particularly hepatitis c virus ns3-ns4a protease, incorporating a fused ring system
NO20072286L (no) Hemming av HCV NS3-NS4A-protease
WO2004072243A3 (en) Macrocyclic hepatitis c serine protease inhibitors
WO2008002924A3 (en) Quinoxalinyl macrocyclic hepatitis c virus serine protease inhibitors
WO2003087092A3 (en) Inhibitors of serine proteases, particularly hepatitis c virus ns3 - ns4 protease
WO2008021960A3 (en) Triazolyl macrocyclic hepatitis c serine protease inhibitors
WO2009053828A3 (en) P3 hydroxyamino macrocyclic hepatitis c serine protease inhibitors
WO2008021871A3 (en) Triazolyl acyclic hepatitis c serine protease inhibitors
NO20060981L (no) Pyridazinderivater og deres anvendelse som terapeutiske midler
WO2007143694A3 (en) Macrocyclic oximyl hepatitis c protease inhibitors
WO2008106058A3 (en) Inhibitors of serine proteases
WO2008022006A3 (en) Arylalkoxyl hepatitis c virus protease inhibitors
WO2009076173A3 (en) Fluorinated tripeptide hcv serine protease inhibitors
MX2010006209A (es) Derivados de quinoxalinilo.
WO2008019303A3 (en) Pyridazinonyl macrocyclic hepatitis c serine protease inhibitors
WO2008019266A3 (en) Acyclic, pyridazinone-derived hepatitis c serine protease inhibitors

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application